Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Mupirocin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IARS1 | P41252 | 4/20 | 1.00 |
| ▸ | HTR2A | P28223 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Mupirocin SCHEMBL18998277 | 1.00 | IARS1 (1.00) | IARS1HTR2A | |
| Mupirocin SCHEMBL19183296 | 1.00 | IARS1 (1.00) | IARS1HTR2A | |
| Mupirocin SCHEMBL15387505 | 1.00 | IARS1 (1.00) | IARS1HTR2A | |
| Mupirocin SCHEMBL3291 | 1.00 | IARS1 (1.00) | IARS1HTR2A | |
| Mupirocin SCHEMBL15387504 | 1.00 | IARS1 (1.00) | IARS1HTR2A | |
| Mupirocin SCHEMBL14616863 | 1.00 | IARS1 (1.00) | IARS1HTR2A | |
| Mupirocin SCHEMBL14022405 | 1.00 | IARS1 (1.00) | IARS1HTR2A | |
| Mupirocin SCHEMBL19008136 | 1.00 | IARS1 (1.00) | IARS1HTR2A | |
| Mupirocin SCHEMBL13011210 | 1.00 | IARS1 (1.00) | IARS1HTR2A | |
| Mupirocin SCHEMBL2223711 | 1.00 | IARS1 (1.00) | IARS1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230346717-A1 | IDENTIFICATION AND USE OF COMPOUNDS IN THE TREATMENT OR PREVENTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 | VANDA PHARMACEUTICALS INC. | 2023-11-02 | — | — | US | disclosed |
| EP-4126235-A2 | IDENTIFICATION AND USE OF COMPOUNDS IN THE TREATMENT OR PREVENTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 | Vanda Pharmaceuticals Inc. (US) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021195470-A2 | IDENTIFICATION AND USE OF COMPOUNDS IN THE TREATMENT OR PREVENTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 | VANDA PHARMACEUTICALS INC. (US) | 2021-09-30 | — | — | WO | disclosed |
| EP-3142642-B1 | LIPOSOMAL MUPIROCIN | YISSUM RES DEV CO OF HEBREW UNIV JERUSALEM LTD (IL) | 2018-08-29 | — | — | EP | disclosed |
| US-10004688-B2 | Liposomal mupirocin | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2018-06-26 | — | — | US | disclosed |
| EP-3142642-A1 | LIPOSOMAL MUPIROCIN | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2017-03-22 | — | — | EP | disclosed |
| US-20170027869-A1 | LIPOSOMAL MUPIROCIN | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2017-02-02 | — | — | US | disclosed |
| US-9205149-B2 | Pharmaceutical topical composition of mupirocin | LABORATORIOS OJER PHARMA, S.L. (ES) | 2015-12-08 | — | — | US | disclosed |
| WO-2015155773-A1 | LIPOSOMAL MUPIROCIN | YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM LTD. (IL) | 2015-10-15 | — | — | WO | disclosed |
| EP-2629756-B1 | PHARMACEUTICAL TOPICAL COMPOSITION OF MUPIROCIN | OJER PHARMA S L LAB (ES) | 2014-12-24 | — | — | EP | disclosed |
| EP-2181330-B1 | COMPOSITIONS AND MEANS FOR DIAGNOSING MICROBIAL INFECTIONS | STATENS SERUMINSTITUT (DK) | 2013-11-20 | — | — | EP | disclosed |
| US-20130267587-A1 | PHARMACEUTICAL TOPICAL COMPOSITION OF MUPIROCIN | LABORATORIOS OJER PHARMA, S.L. (ES) | 2013-10-10 | — | — | US | disclosed |
| EP-2629756-A1 | PHARMACEUTICAL TOPICAL COMPOSITION OF MUPIROCIN | Laboratorios Ojer Pharma S.L. (ES) | 2013-08-28 | — | — | EP | disclosed |
| WO-2012052472-A1 | PHARMACEUTICAL TOPICAL COMPOSITION OF MUPIROCIN | LABORATORIOS OJER PHARMA S.L. (ES) | 2012-04-26 | — | — | WO | disclosed |
| EP-2444067-A1 | Anhydrous gel comprising mupirocin | Laboratorios Ojer Pharma S.L. (ES) | 2012-04-25 | — | — | EP | disclosed |
| EP-2273974-A2 | PROGUANIL TO TREAT SKIN/MUCOSAL DISEASES | Tolmar, Inc. (US) | 2011-01-19 | — | — | EP | disclosed |
| WO-2009137100-A2 | PROGUANIL TO TREAT SKIN/MUCOSAL DISEASES | TOLMAR, INC. (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090280069-A1 | PROGUANIL TO TREAT SKIN/MUCOSAL DISEASES | TOLMAR, INC. (US) | 2009-11-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130267587-A1 | PHARMACEUTICAL TOPICAL COMPOSITION OF MUPIROCIN | CUTA, MGLL, PLIN3 | IARS1 2576/4885HTR2A 4126/4885 |
| US-10004688-B2 | Liposomal mupirocin | LIPA, MAN2B1, MPI | IARS1 2174/4885HTR2A 3790/4885 |
| US-20090280069-A1 | PROGUANIL TO TREAT SKIN/MUCOSAL DISEASES | PROKR1, PROKR2, MC1R | IARS1 2240/4885HTR2A 673/4885 |
| US-20170027869-A1 | LIPOSOMAL MUPIROCIN | LIPA, MAN2B1, MPI | IARS1 2174/4885HTR2A 3790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.